Your browser doesn't support javascript.
loading
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Orozco-Leal, Giovany; Johnson, Eugenie Evelynne; Hosseinijebeli, Sedighe; Robinson, Tomos; Homer, Tara; Eastaugh, Claire H; Richmond, Catherine; Tanner, Louise; Meader, Nick; Kenny, Ryan; Wallace, Sheila A; Rice, Stephen.
Affiliation
  • Orozco-Leal G; Newcastle University, Newcastle upon Tyne, UK.
  • Johnson EE; Newcastle University, Newcastle upon Tyne, UK.
  • Hosseinijebeli S; Newcastle University, Newcastle upon Tyne, UK.
  • Robinson T; Newcastle University, Newcastle upon Tyne, UK.
  • Homer T; Newcastle University, Newcastle upon Tyne, UK.
  • Eastaugh CH; Newcastle University, Newcastle upon Tyne, UK.
  • Richmond C; Clinical Effectiveness Librarian, Tyne and Wear NHS Foundation Trust, Gateshead, UK.
  • Tanner L; Newcastle University, Newcastle upon Tyne, UK.
  • Meader N; Newcastle University, Newcastle upon Tyne, UK.
  • Kenny R; Newcastle University, Newcastle upon Tyne, UK.
  • Wallace SA; Newcastle University, Newcastle upon Tyne, UK.
  • Rice S; Newcastle University, Newcastle upon Tyne, UK. stephen.rice@newcastle.ac.uk.
Pharmacoeconomics ; 42(2): 133-136, 2024 Feb.
Article de En | MEDLINE | ID: mdl-37985576

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Antinéoplasiques immunologiques / Tumeurs du poumon Limites: Humans Langue: En Journal: Pharmacoeconomics Sujet du journal: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Antinéoplasiques immunologiques / Tumeurs du poumon Limites: Humans Langue: En Journal: Pharmacoeconomics Sujet du journal: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni